FDA Approves World’s Most Expensive Drug at $3.5 Million Per Dose to Treat Hemophilia

The U.S. Food and Drug Administration (FDA) has approved CSL Behring’s hemophilia B gene therapy, a one-off infusion attraction with a database terms of $3.5 million, making it the world’s astir costly medicine. The support of CSL Behring’s Hemgenix “provides a caller attraction enactment for patients with Hemophilia B and represents important advancement successful the improvement of innovative therapies for those experiencing a precocious load o...